Export Ready — 

Chronic urticaria in the real-life clinical practice setting in Portugal: 2-years results from the non-interventional multicenter AWARE study

Bibliographic Details
Main Author: Costa, Célia
Publication Date: 2022
Other Authors: Rosmaninho, Isabel, Portuguese Study Investigational Group, On behalf of the AWARE
Format: Article
Language: eng
Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Download full: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/14477
Summary: Introduction: Information regarding chronic urticaria patients in the real-world setting is scarce. This analysis reports the two-year results of Portuguese patients included in the AWARE study.Material and Methods: Non-interventional cohort study. Adult patients with a diagnosis of chronic urticaria with symptoms for at least two months, refractory to H1-antihistamines, consulting one of the 10 participating urticaria centers throughout Portugal, from the 31st October 2014 to 31st July 2015, have been included in the study. Clinical parameters, medicines taken for urticaria symptom relief, weekly urticaria activity score, and dermatology quality of life index have been collected throughout the two years of the study.Results: Seventy-six patients were enrolled in the study. Results showed that the proportion of patients with omalizumab therapy almost duplicated after two years of the AWARE study, which was accompanied by the decrease of medical resources use and absenteeism. Moreover, urticaria severity and impact on quality of life both decreased after one year and continued to decrease at two years, although decreased severity was significant at both time points and quality of life was only significant at two years. At the end of two years, 79.0% of patients had their disease controlled compared to 29.3% at baseline (p < 0.001).Discussion: At the end of the AWARE study a significant proportion of patients had their disease controlled allowing for decreased use of medical resources.Conclusion: Chronic urticaria still has a significant impact on quality of life and therefore there is opportunity for further therapy optimization.
id RCAP_a0c4957530f7e4e6bbc770b35c521aab
oai_identifier_str oai:ojs.www.actamedicaportuguesa.com:article/14477
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling Chronic urticaria in the real-life clinical practice setting in Portugal: 2-years results from the non-interventional multicenter AWARE studyUrticária Crónica na Prática Clínica de Vida Real em Portugal: Resultados de Dois Anos do Estudo Não Intervencional de Vida-Real AWAREUrticaria/classificationUrticaria/diagnosisUrticaria/therapyUrticaria/classificaçãoUrticaria/diagnósticoUrticaria/tratamentoIntroduction: Information regarding chronic urticaria patients in the real-world setting is scarce. This analysis reports the two-year results of Portuguese patients included in the AWARE study.Material and Methods: Non-interventional cohort study. Adult patients with a diagnosis of chronic urticaria with symptoms for at least two months, refractory to H1-antihistamines, consulting one of the 10 participating urticaria centers throughout Portugal, from the 31st October 2014 to 31st July 2015, have been included in the study. Clinical parameters, medicines taken for urticaria symptom relief, weekly urticaria activity score, and dermatology quality of life index have been collected throughout the two years of the study.Results: Seventy-six patients were enrolled in the study. Results showed that the proportion of patients with omalizumab therapy almost duplicated after two years of the AWARE study, which was accompanied by the decrease of medical resources use and absenteeism. Moreover, urticaria severity and impact on quality of life both decreased after one year and continued to decrease at two years, although decreased severity was significant at both time points and quality of life was only significant at two years. At the end of two years, 79.0% of patients had their disease controlled compared to 29.3% at baseline (p < 0.001).Discussion: At the end of the AWARE study a significant proportion of patients had their disease controlled allowing for decreased use of medical resources.Conclusion: Chronic urticaria still has a significant impact on quality of life and therefore there is opportunity for further therapy optimization.Introdução: A informação disponível sobre doentes com urticária crónica em contexto da prática clínica real é escassa. Esta análise reporta os resultados a dois anos dos doentes portugueses incluídos no estudo AWARE.Material e Métodos: Estudo de coorte, observacional, prospectivo, de doentes adultos com diagnóstico de urticária crónica, com sintomas há pelo menos dois meses, refratários a antihístamínicos-H1 na dose aprovada, seguidos em 10 centros de urticária em Portugal, incluídos entre 31 de outubro de 2014 e 31 de julho de 2015. Ao longo dos dois anos do estudo AWARE foram avaliados parâmetros clínicos, medicação utilizada para alívio dos sintomas de urticária, o Weekly Urticaria Activity Score e o índice de qualidade de vida dermatológico.Resultados: Foram incluídos setenta e seis doentes. Após dois anos do estudo AWARE, a percentagem de doentes sob terapia com omalizumab quase duplicou, sendo acompanhada por uma diminuição da utilização de recursos médicos e absenteísmo. A gravidade da urticária e o impacto na qualidade de vida diminuíram após um ano e continuaram a diminuir aos dois anos, embora o aumento da qualidade de vida apenas tenha atingido significado estatístico no segundo ano. A percentagem de doentes com patologia controlada aumentou de 29,3% no início do estudo para 79,0% (p < 0,001).Discussão: No final do estudo AWARE, uma percentagem significativa de doentes apresentou a patologia controlada, permitindo uma diminuição na utilização dos recursos médicos.Conclusão: A urticária crónica tem impacto na qualidade de vida da população, mostrando que a terapêutica ainda poderá ser otimizada.Ordem dos Médicos2022-01-03info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfapplication/pdfapplication/pdfapplication/vnd.openxmlformats-officedocument.wordprocessingml.documenthttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/14477oai:ojs.www.actamedicaportuguesa.com:article/14477Acta Médica Portuguesa; Vol. 35 No. 1 (2022): January; 12-19Acta Médica Portuguesa; Vol. 35 N.º 1 (2022): Janeiro; 12-191646-07580870-399Xreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAPenghttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/14477https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/14477/6377https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/14477/12800https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/14477/12801https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/14477/13059Direitos de Autor (c) 2021 Acta Médica Portuguesainfo:eu-repo/semantics/openAccessCosta, CéliaRosmaninho, IsabelPortuguese Study Investigational Group, On behalf of the AWARE2022-12-20T11:07:13Zoai:ojs.www.actamedicaportuguesa.com:article/14477Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T10:42:19.415859Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv Chronic urticaria in the real-life clinical practice setting in Portugal: 2-years results from the non-interventional multicenter AWARE study
Urticária Crónica na Prática Clínica de Vida Real em Portugal: Resultados de Dois Anos do Estudo Não Intervencional de Vida-Real AWARE
title Chronic urticaria in the real-life clinical practice setting in Portugal: 2-years results from the non-interventional multicenter AWARE study
spellingShingle Chronic urticaria in the real-life clinical practice setting in Portugal: 2-years results from the non-interventional multicenter AWARE study
Costa, Célia
Urticaria/classification
Urticaria/diagnosis
Urticaria/therapy
Urticaria/classificação
Urticaria/diagnóstico
Urticaria/tratamento
title_short Chronic urticaria in the real-life clinical practice setting in Portugal: 2-years results from the non-interventional multicenter AWARE study
title_full Chronic urticaria in the real-life clinical practice setting in Portugal: 2-years results from the non-interventional multicenter AWARE study
title_fullStr Chronic urticaria in the real-life clinical practice setting in Portugal: 2-years results from the non-interventional multicenter AWARE study
title_full_unstemmed Chronic urticaria in the real-life clinical practice setting in Portugal: 2-years results from the non-interventional multicenter AWARE study
title_sort Chronic urticaria in the real-life clinical practice setting in Portugal: 2-years results from the non-interventional multicenter AWARE study
author Costa, Célia
author_facet Costa, Célia
Rosmaninho, Isabel
Portuguese Study Investigational Group, On behalf of the AWARE
author_role author
author2 Rosmaninho, Isabel
Portuguese Study Investigational Group, On behalf of the AWARE
author2_role author
author
dc.contributor.author.fl_str_mv Costa, Célia
Rosmaninho, Isabel
Portuguese Study Investigational Group, On behalf of the AWARE
dc.subject.por.fl_str_mv Urticaria/classification
Urticaria/diagnosis
Urticaria/therapy
Urticaria/classificação
Urticaria/diagnóstico
Urticaria/tratamento
topic Urticaria/classification
Urticaria/diagnosis
Urticaria/therapy
Urticaria/classificação
Urticaria/diagnóstico
Urticaria/tratamento
description Introduction: Information regarding chronic urticaria patients in the real-world setting is scarce. This analysis reports the two-year results of Portuguese patients included in the AWARE study.Material and Methods: Non-interventional cohort study. Adult patients with a diagnosis of chronic urticaria with symptoms for at least two months, refractory to H1-antihistamines, consulting one of the 10 participating urticaria centers throughout Portugal, from the 31st October 2014 to 31st July 2015, have been included in the study. Clinical parameters, medicines taken for urticaria symptom relief, weekly urticaria activity score, and dermatology quality of life index have been collected throughout the two years of the study.Results: Seventy-six patients were enrolled in the study. Results showed that the proportion of patients with omalizumab therapy almost duplicated after two years of the AWARE study, which was accompanied by the decrease of medical resources use and absenteeism. Moreover, urticaria severity and impact on quality of life both decreased after one year and continued to decrease at two years, although decreased severity was significant at both time points and quality of life was only significant at two years. At the end of two years, 79.0% of patients had their disease controlled compared to 29.3% at baseline (p < 0.001).Discussion: At the end of the AWARE study a significant proportion of patients had their disease controlled allowing for decreased use of medical resources.Conclusion: Chronic urticaria still has a significant impact on quality of life and therefore there is opportunity for further therapy optimization.
publishDate 2022
dc.date.none.fl_str_mv 2022-01-03
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/14477
oai:ojs.www.actamedicaportuguesa.com:article/14477
url https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/14477
identifier_str_mv oai:ojs.www.actamedicaportuguesa.com:article/14477
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/14477
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/14477/6377
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/14477/12800
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/14477/12801
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/14477/13059
dc.rights.driver.fl_str_mv Direitos de Autor (c) 2021 Acta Médica Portuguesa
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Direitos de Autor (c) 2021 Acta Médica Portuguesa
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/vnd.openxmlformats-officedocument.wordprocessingml.document
dc.publisher.none.fl_str_mv Ordem dos Médicos
publisher.none.fl_str_mv Ordem dos Médicos
dc.source.none.fl_str_mv Acta Médica Portuguesa; Vol. 35 No. 1 (2022): January; 12-19
Acta Médica Portuguesa; Vol. 35 N.º 1 (2022): Janeiro; 12-19
1646-0758
0870-399X
reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833591137699364864